Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, Saeed Sadeghi, Teresa Macarulla, Karl Heinz Weiss, Dirk Thomas Waldschmidt, Lipika Goyal, Ivan Borbath, Anthony El-Khoueiry, Mitesh J. Borad, Wei Peng Yong, Philip A. Philip, Michael Bitzer, Surbpong Tanasanvimon, Ai Li, Amit Pande, Harris S. Soifer, Stacie Peacock Shepherd, Susan MoranAndrew X. Zhu, Tanios S. Bekaii-Saab, Ghassan K. Abou-Alfa
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study'. Together they form a unique fingerprint.